Durvalumab with or without tremelimumab in combination with chemotherapy in first-line metastatic non-small-cell lung cancer: outcomes by tumor mutational burden in POSEIDON
- DOI
- 10.1016/j.esmoop.2025.105058
- Published
- 2025-05
- Container
- ESMO Open
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.esmoop.2025.105058,
title = {Durvalumab with or without tremelimumab in combination with chemotherapy in first-line metastatic non-small-cell lung cancer: outcomes by tumor mutational burden in POSEIDON},
author = {S. Peters and K.S. Oliner and A. L’Hernault and M. Ratcliffe and H. Madison and Z. Lai and R. Stewart and H. Mann and C. Lowery and E.B. Garon and T. Mok and M.L. Johnson},
year = {2025},
journal = {ESMO Open},
doi = {10.1016/j.esmoop.2025.105058},
url = {https://doi.org/10.1016/j.esmoop.2025.105058}
}RIS
TY - JOUR TI - Durvalumab with or without tremelimumab in combination with chemotherapy in first-line metastatic non-small-cell lung cancer: outcomes by tumor mutational burden in POSEIDON AU - S. Peters AU - K.S. Oliner AU - A. L’Hernault AU - M. Ratcliffe AU - H. Madison AU - Z. Lai AU - R. Stewart AU - H. Mann AU - C. Lowery AU - E.B. Garon AU - T. Mok AU - M.L. Johnson PY - 2025 JO - ESMO Open DO - 10.1016/j.esmoop.2025.105058 UR - https://doi.org/10.1016/j.esmoop.2025.105058 ER -
APA
Peters, S., Oliner, K., L’Hernault, A., Ratcliffe, M., Madison, H., Lai, Z., Stewart, R., Mann, H., Lowery, C., Garon, E., Mok, T., & Johnson, M. (2025). Durvalumab with or without tremelimumab in combination with chemotherapy in first-line metastatic non-small-cell lung cancer: outcomes by tumor mutational burden in POSEIDON. ESMO Open. https://doi.org/10.1016/j.esmoop.2025.105058
Source records
- crossref · retrieved 2026-09-26T22:38:29.431Z